Markus F. Renschler

11.9k total citations · 1 hit paper
74 papers, 4.0k citations indexed

About

Markus F. Renschler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Markus F. Renschler has authored 74 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Markus F. Renschler's work include Brain Metastases and Treatment (27 papers), Lung Cancer Research Studies (25 papers) and Lung Cancer Treatments and Mutations (18 papers). Markus F. Renschler is often cited by papers focused on Brain Metastases and Treatment (27 papers), Lung Cancer Research Studies (25 papers) and Lung Cancer Treatments and Mutations (18 papers). Markus F. Renschler collaborates with scholars based in United States, Canada and Germany. Markus F. Renschler's co-authors include Minesh P. Mehta, Søren M. Bentzen, Mark A. Socinski, Vera Hirsh, Isamu Okamoto, Jeremy K. Hon, Jennifer A. Smith, Richard Miller, Jing Li and J. L. Mesías Iglesias and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Oncology.

In The Last Decade

Markus F. Renschler

73 papers receiving 3.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Mark A. Socinski, Isamu Okamoto et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus F. Renschler United States	28	2.4k	2.2k	1.1k	891	689	74	4.0k
Hilary Calvert United Kingdom	31	1.5k 0.7×	2.6k 1.2×	765 0.7×	2.2k 2.5×	198 0.3×	79	5.0k
Petr Kavan Canada	29	1.1k 0.5×	1.5k 0.7×	2.0k 1.9×	1.0k 1.1×	377 0.5×	141	4.4k
Paul de Souza Australia	38	2.1k 0.9×	3.2k 1.4×	939 0.9×	1.9k 2.1×	213 0.3×	152	6.2k
T Inomata Japan	16	2.2k 0.9×	1.1k 0.5×	1.4k 1.4×	229 0.3×	739 1.1×	79	2.9k
Steven J. Chmura United States	39	2.5k 1.1×	2.5k 1.1×	576 0.5×	1.0k 1.1×	306 0.4×	172	6.0k
Raul C. Urtasun Canada	34	1.8k 0.7×	733 0.3×	1.8k 1.7×	646 0.7×	504 0.7×	89	3.9k
Mary Malec United States	24	969 0.4×	533 0.2×	1.9k 1.8×	718 0.8×	471 0.7×	34	3.0k
Qichun Wei China	30	620 0.3×	903 0.4×	222 0.2×	1.2k 1.3×	200 0.3×	138	3.2k
Denice Tsao‐Wei United States	33	919 0.4×	2.1k 0.9×	202 0.2×	1.9k 2.1×	355 0.5×	116	4.7k
Carsten Herskind Germany	31	1.1k 0.5×	663 0.3×	278 0.3×	787 0.9×	167 0.2×	123	3.1k

Countries citing papers authored by Markus F. Renschler

Since Specialization

Citations

This map shows the geographic impact of Markus F. Renschler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus F. Renschler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus F. Renschler more than expected).

Fields of papers citing papers by Markus F. Renschler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus F. Renschler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus F. Renschler. The network helps show where Markus F. Renschler may publish in the future.

Co-authorship network of co-authors of Markus F. Renschler

This figure shows the co-authorship network connecting the top 25 collaborators of Markus F. Renschler. A scholar is included among the top collaborators of Markus F. Renschler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus F. Renschler. Markus F. Renschler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Korn, Ronald L., Daniel D. Von Hoff, Mitesh J. Borad, et al.. (2017). 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Cancer Imaging. 17(1). 23–23. 6 indexed citations

Goldstein, David, Daniel D. Von Hoff, Elena G. Chiorean, et al.. (2017). Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer. Annals of Oncology. 28. iii142–iii144.

Langer, Corey J., Vera Hirsh, Isamu Okamoto, et al.. (2015). Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. British Journal of Cancer. 113(1). 20–29. 14 indexed citations

Binder, G., et al.. (2014). Magnitude of Benefit and Costs for Recent Solid Tumor Agents. Value in Health. 17(3). A69–A69. 1 indexed citations

Socinski, Mark A., Isamu Okamoto, Jeremy K. Hon, et al.. (2013). Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Annals of Oncology. 24(9). 2390–2396. 57 indexed citations

Hoff, Daniel D. Von, Thomas J. Ervin, Francis P. Arena, et al.. (2013). Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. Journal of Clinical Oncology. 31(4_suppl). LBA148–LBA148. 90 indexed citations

Socinski, Mark A., Corey J. Langer, Isamu Okamoto, et al.. (2012). Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Annals of Oncology. 24(2). 314–321. 92 indexed citations

Renschler, Markus F., Isamu Okamoto, Jeremy K. Hon, et al.. (2012). Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). 7592–7592. 4 indexed citations

Li, Jing, Søren M. Bentzen, Jialiang Li, Markus F. Renschler, & Minesh P. Mehta. (2008). Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. International Journal of Radiation Oncology*Biology*Physics. 71(1). 64–70. 223 indexed citations

10.

Natale, Ronald B., Garth Nicholas, Frank A. Greco, et al.. (2007). PD3-1-8: Motexafin Gadolinium (MGd) is active as a single agent in advanced non-small-cell lung cancer (NSCLC) patients who failed platinum-based chemotherapy: preliminary results of a phase II trial. Journal of Thoracic Oncology. 2(8). S462–S462. 1 indexed citations

11.

Suh, John H., Minesh P. Mehta, Anne Dagnault, et al.. (2006). 1110. International Journal of Radiation Oncology*Biology*Physics. 66(3). S193–S194. 1 indexed citations

12.

Bentzen, Søren M., et al.. (2006). 155. International Journal of Radiation Oncology*Biology*Physics. 66(3). S87–S87. 3 indexed citations

13.

Miles, Dale, Jennifer A. Smith, See‐Chun Phan, et al.. (2005). Population Pharmacokinetics of Motexafin Gadolinium in Adults With Brain Metastases or Glioblastoma Multiforme. The Journal of Clinical Pharmacology. 45(3). 299–312. 10 indexed citations

14.

Renschler, Markus F.. (2004). The emerging role of reactive oxygen species in cancer therapy. European Journal of Cancer. 40(13). 1934–1940. 197 indexed citations

15.

Meyers, Christina A., Jennifer A. Smith, Andrea Bezjak, et al.. (2003). Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 22(1). 157–165. 423 indexed citations

16.

Carde, Patrice, Robert Timmerman, Minesh P. Mehta, et al.. (2001). Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases. Journal of Clinical Oncology. 19(7). 2074–2083. 109 indexed citations

17.

Mehta, Minesh P., Patrick Rodrigus, Chris H.J. Terhaard, et al.. (2001). Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium. International Journal of Radiation Oncology*Biology*Physics. 51(3). 135–136. 1 indexed citations

18.

Miller, Richard A., Kathryn W. Woodburn, Qing Fan, et al.. (1999). In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. International Journal of Radiation Oncology*Biology*Physics. 45(4). 981–989. 94 indexed citations

19.

Rosenthal, David I., Pamela Nurenberg, Carlos Becerra, et al.. (1999). A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.. PubMed. 5(4). 739–45. 94 indexed citations

20.

Renschler, Markus F., D. Vanel, Vincent P. Mathews, et al.. (1998). Selective uptake and retention of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) in tumors demonstrated by MRI in phase I and II clinical trials. International Journal of Radiation Oncology*Biology*Physics. 42(1). 263–263. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact